×
About 19,578 results

CT-Based Changes in Bone and Marrow Among Patients on Oral Steroids
https://clinicaltrials.gov/ct2/show/NCT04518722

Feb 3rd, 2023 - This study aims to prove that emerging CT-based tools are suitable to measure changes in central and peripheral bone density, geometry, micro-structure, and marrow adipose tissue (MAT) among patients treated with oral steroids. To do this, investigators will recruit 10 non-smokers (defined as < 10 pack-year smoking history) age 25-45 years with a diagnosis of severe, persistent asthma who eithe...

Puberty Suppression and Cardiometabolic Health
https://clinicaltrials.gov/ct2/show/NCT04482374

Feb 3rd, 2023 - This observational study will evaluate the effect of puberty suppression on insulin sensitivity, metabolic rate and vascular health among transgender female youth at baseline and 6 months after initiation of a gondoatropin releasing hormone agonist compared to matched cisgender male controls.

Implementing a Guidelines-Based M-Health Intervention for High Risk Asthma Patients
https://clinicaltrials.gov/ct2/show/NCT03842033

Feb 3rd, 2023 - The proposed project aligns with our prior work targeting high-risk pediatric asthma populations in non-inner city environments by targeting adolescents at risk for future exacerbations from the Patient-Centered Medical Home (PCMH) at Arkansas Children's Hospital (ACH). We propose to conduct a 3-arm randomized, controlled trial with 372 adolescents with uncontrolled asthma to test the effective...

Study of Factors Regulating Mast Cell Proliferation
https://clinicaltrials.gov/ct2/show/NCT00044122

Feb 3rd, 2023 - This protocol is designed to examine those growth potentiating and inhibiting factors which regulate mast cell number and survival in patients with mastocytosis, and to explore the molecular basis of the disease process in hopes of improving therapy. Patients will carry the diagnosis of mastocytosis based on abnormal bone marrow biopsy and aspirate, abnormal skin biopsy, presence of urticaria p...

Dupilumab in Eosinophilic Gastritis
https://clinicaltrials.gov/ct2/show/NCT03678545

Feb 3rd, 2023 - This is a phase 2, multi-center, randomized, double-blind, placebo-controlled trial testing the efficacy of dupilumab vs. placebo in EG. Qualifying subjects will be randomized 1:1 to either study drug (dupilumab) or placebo, and will receive 600 mg once followed by 300 mg doses every two weeks of study treatment for a total of 6 injections. After the 6th injection subjects may continue into an ...

A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT05149131

Feb 3rd, 2023 - This is an observational study in which patient data from the past on men with metastatic castration-sensitive prostate cancer is studied. Metastatic castration-sensitive prostate cancer (mCSPC) is a type of advanced prostate cancer that has spread to other parts of the body, and still responds to treatment that lowers testosterone levels. Cancer is a condition in which the body cannot control ...

Andosan in Allergic and Asthma Patients
https://clinicaltrials.gov/ct2/show/NCT05192720

Feb 3rd, 2023 - Asthma and allergy are increasing in Norway and Western countries. Treatment is still mostly symptomatic. Extracts of the immunomodulatory and edible mushroom Agaricus blazei, such as Andosan™, have been shown to protect against asthma and allergy in murine models by changing the T helper cell 1(upregulation)-T helper cell 2 (downregulation) balance in the immune system. Positive effects on all...

Studies of Skin Microbes in Healthy People and in People With Skin Conditions
https://clinicaltrials.gov/ct2/show/NCT00605878

Feb 3rd, 2023 - Skin microbiota (bacteria, fungi, viruses, phage, archae) play a significant role in common dermatological conditions, such as atopic dermatitis/AD (eczema). Since culture-dependent methods are often biased assessments of microbial diversity, genomic methods can expand our understanding of the human microbiome and skin diseases. Chronic dermatitis is typical among rare primary immunodeficiencie...

Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy
https://clinicaltrials.gov/ct2/show/NCT05440643

Feb 3rd, 2023 - This is a phase I, open-label, dose-escalation, multi-site trial including subjects with peanut allergy confirmed by screening double-blind, placebo-controlled food challenge. The trial is conducted in 2 parts; part 1 will determine the entry dose of the up-dosing regimen (UDR) in adults and part 2 will characterize the tolerability of the up-dosing regimen in adults, adolescents and children. ...

A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma
https://clinicaltrials.gov/ct2/show/NCT05593250

Feb 3rd, 2023 - This study is a phase 2 study of SHR-1905 in subjects with severe uncontrolled asthma. The purpose of the study is to evaluate efficacy and safety of SHR-1905 in subjects with severe uncontrolled asthma.

Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT05018806

Feb 3rd, 2023 - This is a parallel, treatment, Phase 2, double-blind, 2-arm, placebo-controlled study with 2 staggered cohorts (2 arms in each cohort) to evaluate the efficacy and safety of rilzabrutinib in adult participants (aged at least 18 years) with moderate-to-severe AD and intolerance or inadequate response to topical corticosteroids (TCS). In parallel to the main study, Japanese participants will be e...

Telemedicine System and Intelligent Monitoring System Construction of Pediatric Asthma Based on the Electronic Stethoscope
https://clinicaltrials.gov/ct2/show/NCT05659225

Feb 3rd, 2023 - (1) The design of hardware and software of the intelligent electronic stethoscope This project will optimize and develop the software and hardware equipment of electronic stethoscope according to the shortcomings of existing electronic stethoscopes. Get high-quality breath sound data through integrated ECG sensor and algorithms for denoising and the separation of heart sound and lung sound Deve...

A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT05656911

Feb 3rd, 2023 - Researchers are looking for a better way to treat atopic dermatitis (AD), an often long-lasting inflammation of the skin. Atopic dermatitis, also called eczema, is causing patches of skin to become swollen, red, cracked, and itchy. The immune system helps protect the body from diseases. But sometimes the immune system can be too sensitive and overreact. This may then lead to allergies but also ...

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT05601882

Feb 3rd, 2023 - Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study compares upadacitinib to dupilumab in adolescent and adult participants with moderate to severe AD who have inadequate response to system...

Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab
https://clinicaltrials.gov/ct2/show/NCT04210843

Feb 2nd, 2023 - The purpose of this extension study was to establish efficacy and safety of ligelizumab. This was assessed in adult and adolescent chronic spontaneous urticaria (CSU) patients who had completed a preceding ligelizumab study and have relapsed, following treatment in these preceding studies, despite standard of care H1-antihistamine (H1-AH) treatment. In a subset of subjects, the safety and effic...

Food Allergen OIT for Shrimp and Cashew
https://clinicaltrials.gov/ct2/show/NCT03504774

Feb 2nd, 2023 - A prospective Phase 2, single-center, single-allergen OIT of cashew or shrimp in participants with proven allergies to either cashew or shrimp, respectively. We intend to treat 72 participants, ages 7 to 55 years with an allergy to either cashew or shrimp determined by Double Blind-Placebo Controlled-Food Challenge (DBPCFC), allergy history, clinical symptoms, food-allergen (FA)-specific IgE le...

Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma
https://clinicaltrials.gov/ct2/show/NCT03927157

Feb 2nd, 2023 - This is a regional, multicentre, randomized, double-blind, placebo controlled, parallel group, phase 3 study designed to evaluate the efficacy and safety of 210 mg Q4W (SC) of tezepelumab in adults with severe, uncontrolled asthma on medium to high-dose ICS and at least one additional asthma controller medication with or without OCS. Approximately 396 participants will be randomized regionally ...

A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients
https://clinicaltrials.gov/ct2/show/NCT00819637

Feb 2nd, 2023 - Acute bronchospasm associated with exacerbations of asthma is a common problem. Currently the mainstay of treatment is inhalation albuterol, either levalbuterol or racemic mixture, in repetitive fashion depending on the resolution of the airways obstruction. Formoterol is a long-acting (>12 hours) selective beta2-agonist that has a very rapid onset of bronchodilatation (<3 minutes and thus simi...

Severe Asthma Research Program
https://clinicaltrials.gov/ct2/show/NCT01606826

Feb 2nd, 2023 - The mission of the SARP is to improve the understanding of severe asthma to develop better treatments. The SARP will gain a better understanding of asthma and its endotypes, in children and adults, by defining the disease at the molecular and cellular levels in the context of the temporal phenotypic expression of the disease. To this end, the SARP investigators will utilize both mechanistic and...

Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
https://clinicaltrials.gov/ct2/show/NCT03953300

Feb 2nd, 2023 - The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics. Changes will be assessed over 48 week treatment period in patients with persistent symptoms despite standard therapy of inhaled corticosteroids (ICS) plus long acting B2-agonist (LABA) with or without additional controller medication. Patients who complete tr...